Roche/GSK Boniva price
Executive Summary
The wholesale acquisition cost of Roche/GlaxoSmithKline's once-monthly osteoporosis agent Boniva (ibandronate) is $64.28 per tablet, comparable to the monthly cost of Merck's once-weekly Fosamax. Roche/GSK plan to launch Boniva by the end of April (1"The Pink Sheet" April 4, 2005, p. 4)...
You may also be interested in...
Roche/GSK Boniva Launch Plan Includes Reminders For Once-Monthly Dose
Roche and GlaxoSmithKline will support the launch of the osteoporosis therapy Boniva (ibandronate) with a program intended to help patients comply with the once-monthly oral dosing regimen
AACR Round-Up: BMS, Lilly, iTeos, Affimed, Treovir, Revolution And Cardiff
iTeos presents early anti-TIGIT results, Affimed reports 100% response rate in Hodgkin lymphoma, Treovir will start a pivotal Phase II after Phase I pediatric glioma study, updates in KRAS-mutated cancers from Revolution Medicines and Cardiff Oncology, plus Opdivo plus chemo shows complete responses in neoadjuvant lung cancer and Lilly’s Retevmo is active in additional tumors.
India Remdesivir Saga: Exports Barred, Ramp Up Plans And Panic
India stops remdesivir exports amid steep surge in COVID-19 cases, while licensees of Gilead’s antiviral progress multiple measures to ramp up production to meet local demand. One badly affected state stresses the need to stem panic given the limitations of the treatment, even as some non-licensees of the drug apparently seek to contribute to supplies.